CD274 and hepatocellular carcinoma: Indeed, an emerging regimen involving a PD-L1 monoclonal antibody, atezolizumab, and the VEGF inhibitor bevacizumab has recently received FDA approval for its demonstrated improvement in the overall and progression-free survival in patients with unresectable HCC compared to that of the approved first-line treatment with a multi-kinase inhibitor, sorafenib [124].